ADMA Biologics Inc (ADMA)

Cash ratio

		Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019
Cash and cash equivalents	US$ in thousands	86,707	88,244	45,325	51,352	74,157	62,513	69,204	86,522	34,906	52,415	69,505	51,089	34,411	42,409	61,966	55,921	59,675	75,781	101,236	26,752
Short-term investments	US$ in thousands	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Total current liabilities	US$ in thousands	44,891	44,177	53,088	49,806	41,841	41,952	36,728	39,267	44,440	28,072	31,567	30,378	32,337	18,186	21,206	19,947	16,474	12,880	13,908	14,028
Cash ratio		1.93	2.00	0.85	1.03	1.77	1.49	1.88	2.20	0.79	1.87	2.20	1.68	1.06	2.33	2.92	2.80	3.62	5.88	7.28	1.91

September 30, 2024 calculation

Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($86,707K + $—K) ÷ $44,891K
= 1.93

The cash ratio of ADMA Biologics Inc has shown fluctuations over the past few quarters. As of September 30, 2024, the cash ratio was 1.93, indicating that the company had $1.93 in cash and cash equivalents for every $1 of current liabilities. This ratio has decreased from the previous quarter but remains at a relatively healthy level.

Looking further back, the cash ratio has varied significantly, with values ranging from a low of 0.79 to a high of 7.28 over the past two years. The trend in the cash ratio suggests that the company's liquidity position has been fluctuating, which could be due to changes in the company's cash holdings or its current liabilities.

Overall, the cash ratio provides insights into ADMA Biologics Inc's ability to cover its short-term obligations with its available cash resources. It is important for the company to maintain a sufficient cash ratio to ensure financial stability and meet its financial commitments in a timely manner.